JP2017532374A5 - - Google Patents

Download PDF

Info

Publication number: JP2017532374A5
Authority: JP; Japan
Prior art keywords: mannitol; pharmaceutical composition; eutectic; item; cyclobenzaprine hcl
Prior art date: 2015-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017535609A

Other languages

English (en)

Japanese (ja)

Other versions

JP6614724B2 (ja

JP2017532374A (ja

Filing date

2015-09-18

Publication date

2018-11-01

2015-09-18 Application filed filed Critical

2015-09-18 Priority claimed from PCT/US2015/051068 external-priority patent/WO2016044796A1/en

2017-11-02 Publication of JP2017532374A publication Critical patent/JP2017532374A/ja

2018-11-01 Publication of JP2017532374A5 publication Critical patent/JP2017532374A5/ja

2019-12-04 Application granted granted Critical

2019-12-04 Publication of JP6614724B2 publication Critical patent/JP6614724B2/ja

Status Active legal-status Critical Current

2035-09-18 Anticipated expiration legal-status Critical

Links

239000000594 mannitol Substances 0.000 claims description 45
229930195725 Mannitol Natural products 0.000 claims description 37
235000010355 mannitol Nutrition 0.000 claims description 37
229960003572 cyclobenzaprine Drugs 0.000 claims description 36
JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 35
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 32
239000008194 pharmaceutical composition Substances 0.000 claims description 26
230000005496 eutectics Effects 0.000 claims description 25
238000000034 method Methods 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
238000005550 wet granulation Methods 0.000 claims description 10
239000008187 granular material Substances 0.000 claims description 9
238000002156 mixing Methods 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
239000000155 melt Substances 0.000 claims description 6
239000002610 basifying agent Substances 0.000 claims description 4
238000002425 crystallisation Methods 0.000 claims description 4
230000008025 crystallization Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 2
230000001419 dependent effect Effects 0.000 claims 2
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims 1
239000000463 material Substances 0.000 claims 1
229940058023 trisodium citrate anhydrous Drugs 0.000 claims 1
239000002245 particle Substances 0.000 description 5
238000000634 powder X-ray diffraction Methods 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000000320 mechanical mixture Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

JP2017535609A 2014-09-18 2015-09-18 シクロベンザプリン塩酸塩の共融製剤 Active JP6614724B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462052238P	2014-09-18	2014-09-18
US62/052,238		2014-09-18
PCT/US2015/051068 WO2016044796A1 (en)	2014-09-18	2015-09-18	Eutectic formulations of cyclobenzaprine hydrochloride

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018173466A Division JP6717902B6 (ja)	2014-09-18	2018-09-18	シクロベンザプリン塩酸塩の共融製剤

Publications (3)

Publication Number	Publication Date
JP2017532374A JP2017532374A (ja)	2017-11-02
JP2017532374A5 true JP2017532374A5 (2)	2018-11-01
JP6614724B2 JP6614724B2 (ja)	2019-12-04

Family

ID=55533932

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
JP2017535609A Active JP6614724B2 (ja)	2014-09-18	2015-09-18	シクロベンザプリン塩酸塩の共融製剤
JP2018173466A Active JP6717902B6 (ja)	2014-09-18	2018-09-18	シクロベンザプリン塩酸塩の共融製剤
JP2019236602A Withdrawn JP2020059757A (ja)	2014-09-18	2019-12-26	シクロベンザプリン塩酸塩の共融製剤
JP2021169539A Withdrawn JP2022001605A (ja)	2014-09-18	2021-10-15	シクロベンザプリン塩酸塩の共融製剤
JP2023116057A Withdrawn JP2023126486A (ja)	2014-09-18	2023-07-14	シクロベンザプリン塩酸塩の共融製剤
JP2025076812A Pending JP2025107355A (ja)	2014-09-18	2025-05-02	シクロベンザプリン塩酸塩の共融製剤

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
JP2018173466A Active JP6717902B6 (ja)	2014-09-18	2018-09-18	シクロベンザプリン塩酸塩の共融製剤
JP2019236602A Withdrawn JP2020059757A (ja)	2014-09-18	2019-12-26	シクロベンザプリン塩酸塩の共融製剤
JP2021169539A Withdrawn JP2022001605A (ja)	2014-09-18	2021-10-15	シクロベンザプリン塩酸塩の共融製剤
JP2023116057A Withdrawn JP2023126486A (ja)	2014-09-18	2023-07-14	シクロベンザプリン塩酸塩の共融製剤
JP2025076812A Pending JP2025107355A (ja)	2014-09-18	2025-05-02	シクロベンザプリン塩酸塩の共融製剤

Country Status (12)

Country	Link
US (2)	US10357465B2 (2)
EP (1)	EP3193854A4 (2)
JP (6)	JP6614724B2 (2)
CN (2)	CN107072968B (2)
AU (2)	AU2015317336B2 (2)
BR (1)	BR112017005231A2 (2)
IL (2)	IL251218B (2)
MX (1)	MX387402B (2)
MY (1)	MY186047A (2)
SG (2)	SG11201701995PA (2)
WO (1)	WO2016044796A1 (2)
ZA (1)	ZA201701637B (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20171739T1 (hr)	2009-11-20	2018-03-09	Tonix Pharma Holdings Limited	Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en)	2010-06-24	2011-12-29	Tonix Pharmaceuticals, Inc.	Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en)	2011-03-07	2024-06-04	Tonix Pharma Holdings Limited	Methods and compositions for treating depression using cyclobenzaprine
JP6310542B2 (ja)	2013-03-15	2018-04-11	トニックスファーマシューティカルズ，インコーポレイテッド	シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤
SG11201701995PA (en) *	2014-09-18	2017-04-27	Tonix Pharma Holdings Ltd	Eutectic formulations of cyclobenzaprine hydrochloride
US11826321B2 (en) *	2017-12-11	2023-11-28	Tonix Pharma Holdings Limited	Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
TW202019400A (zh) *	2018-08-20	2020-06-01	愛爾蘭商托尼克製藥控股有限公司	治療急性壓力症候群及創傷後壓力症候群之方法
NL2023661B1 (en) *	2019-08-19	2021-04-21	Seranovo Holding B V	Pharmaceutical Eutectic Salt Formulation
AU2021253592A1 (en) *	2020-04-08	2022-11-10	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine treatment for sexual dysfunction
MX2023005899A (es) *	2020-11-20	2023-08-16	TONIX Pharmaceuticals Holding Corp	Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
AU2021396509A1 (en) *	2020-12-07	2023-06-29	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine treatment for fibromyalgia
US20240415789A1 (en) *	2021-10-06	2024-12-19	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
WO2023250036A1 (en)	2022-06-21	2023-12-28	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
WO2025160302A1 (en)	2024-01-25	2025-07-31	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968507A (en) *	1984-06-20	1990-11-06	Merck & Co., Inc.	Controlled porosity osmotic pump
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en)	1992-07-31	1998-03-20	Us Bioscience	Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
BR9405798A (pt)	1993-02-22	1995-12-12	Vivorx Pharmaceuticals Inc	Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en)	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US20030077227A1 (en)	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) *	1997-10-16	1999-04-22	Merck & Co., Inc.	New cyclobenzaprine composition
DK1077683T3 (da)	1998-05-14	2003-03-31	Alza Corp	Antidepressiv behandling
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en)	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0013122A (pt)	1999-08-13	2002-04-30	Vela Pharmaceuticals Inc	Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
WO2001012175A1 (en)	1999-08-13	2001-02-22	Vela Pharmaceuticals Inc.	Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en)	2000-05-19	2001-11-29	Npd Llc	Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
EP1441708B1 (en)	2001-11-05	2009-04-08	Krele Pharmaceuticals LLC	Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US7105486B2 (en)	2002-02-22	2006-09-12	New River Pharmaceuticals Inc.	Abuse-resistant amphetamine compounds
US7659253B2 (en)	2002-02-22	2010-02-09	Shire Llc	Abuse-resistant amphetamine prodrugs
US7700561B2 (en)	2002-02-22	2010-04-20	Shire Llc	Abuse-resistant amphetamine prodrugs
CA2503381A1 (en)	2002-10-25	2004-05-13	Collegium Pharmaceutical, Inc.	Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
CN103405405A (zh)	2002-12-09	2013-11-27	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
MXPA05012850A (es)	2003-05-29	2006-05-17	New River Pharmaceuticals Inc	Compuestos de anfetamina resistentes al abuso.
BRPI0415683A (pt)	2003-11-03	2006-12-19	Warner Lambert Co	inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
US20050143350A1 (en)	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
CA2548281C (en)	2003-12-09	2013-11-12	Medcrystalforms, Llc	Method of preparation of mixed phase co-crystals with active agents
JP5179757B2 (ja)	2004-02-17	2013-04-10	トランセプトファーマシューティカルズ，インコーポレイティド	口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US8216610B2 (en)	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
US20070196364A1 (en) *	2004-07-27	2007-08-23	Human Genome Sciences, Inc.	Pharmaceutical Formulation and Process
US7532935B2 (en)	2005-07-29	2009-05-12	Cyberonics, Inc.	Selective neurostimulation for treating mood disorders
US7994220B2 (en)	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080146672A1 (en)	2006-12-08	2008-06-19	Denton Marcia Marye	Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
CA2690737A1 (en)	2007-06-22	2008-12-31	Merck Sharp & Dohme Corp.	6.5-pyrrolopiperidine tachykinin receptor antagonists
JP2010534676A (ja)	2007-07-23	2010-11-11	シノシア・セラピューティクス	心的外傷後ストレス障害の治療
US20090060983A1 (en)	2007-08-30	2009-03-05	Bunick Frank J	Method And Composition For Making An Orally Disintegrating Dosage Form
SI2200588T1 (sl) *	2007-09-25	2019-08-30	Solubest Ltd.	Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
EP2203158A4 (en)	2007-10-30	2012-12-26	Reddys Lab Ltd Dr	PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20090148532A1 (en)	2007-12-06	2009-06-11	Venkatesh Gopi M	Preparation of controlled release skeletal muscle relaxant dosage forms
ES2620672T3 (es)	2008-01-09	2017-06-29	Charleston Laboratories, Inc.	Comprimidos de doble capa que comprenden oxicodona y prometazina
US9314469B2 (en)	2008-05-05	2016-04-19	Tonix Pharma Holdings Limited	Method for treating neurocognitive dysfunction
JP5380909B2 (ja)	2008-05-30	2014-01-08	株式会社ブリヂストン	金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en)	2008-12-10	2010-10-21	Nipun Davar	Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2233134A1 (en)	2009-03-27	2010-09-29	McNeil AB	Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en)	2009-03-27	2010-09-30	Andreas Hugerth	Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US8871263B2 (en)	2009-09-24	2014-10-28	Mcneil-Ppc, Inc.	Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
HRP20171739T1 (hr)	2009-11-20	2018-03-09	Tonix Pharma Holdings Limited	Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en)	2010-06-24	2011-12-29	Tonix Pharmaceuticals, Inc.	Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
WO2012050594A1 (en)	2010-09-01	2012-04-19	Tonix Pharmaceuticals, Inc.	Treatment for cocaine addiction
US11998516B2 (en) *	2011-03-07	2024-06-04	Tonix Pharma Holdings Limited	Methods and compositions for treating depression using cyclobenzaprine
SMT202200436T1 (it) *	2012-06-15	2023-01-13	Tonix Pharma Holdings Ltd	Composizioni e metodi per l’assorbimento transmucosale
JP6310542B2 (ja) *	2013-03-15	2018-04-11	トニックスファーマシューティカルズ，インコーポレイテッド	シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤
SG11201701995PA (en) *	2014-09-18	2017-04-27	Tonix Pharma Holdings Ltd	Eutectic formulations of cyclobenzaprine hydrochloride

2015
- 2015-09-18 SG SG11201701995PA patent/SG11201701995PA/en unknown
- 2015-09-18 SG SG10201902203VA patent/SG10201902203VA/en unknown
- 2015-09-18 CN CN201580050140.2A patent/CN107072968B/zh active Active
- 2015-09-18 MY MYPI2017700889A patent/MY186047A/en unknown
- 2015-09-18 BR BR112017005231A patent/BR112017005231A2/pt not_active Application Discontinuation
- 2015-09-18 MX MX2017003644A patent/MX387402B/es unknown
- 2015-09-18 JP JP2017535609A patent/JP6614724B2/ja active Active
- 2015-09-18 AU AU2015317336A patent/AU2015317336B2/en active Active
- 2015-09-18 WO PCT/US2015/051068 patent/WO2016044796A1/en not_active Ceased
- 2015-09-18 EP EP15841528.1A patent/EP3193854A4/en active Pending
- 2015-09-18 US US15/511,287 patent/US10357465B2/en active Active
- 2015-09-18 CN CN202011576351.9A patent/CN112618494B/zh active Active
2017
- 2017-03-07 ZA ZA2017/01637A patent/ZA201701637B/en unknown
- 2017-03-16 IL IL251218A patent/IL251218B/en active IP Right Grant
2018
- 2018-09-18 JP JP2018173466A patent/JP6717902B6/ja active Active
2019
- 2019-07-22 US US16/518,338 patent/US11026898B2/en active Active
- 2019-12-26 JP JP2019236602A patent/JP2020059757A/ja not_active Withdrawn
2020
- 2020-10-05 IL IL277814A patent/IL277814B/en unknown
- 2020-12-17 AU AU2020289838A patent/AU2020289838B2/en active Active
2021
- 2021-10-15 JP JP2021169539A patent/JP2022001605A/ja not_active Withdrawn
2023
- 2023-07-14 JP JP2023116057A patent/JP2023126486A/ja not_active Withdrawn
2025
- 2025-05-02 JP JP2025076812A patent/JP2025107355A/ja active Pending

Publication	Publication Date	Title
JP2017532374A5 (2)	2018-11-01
CN101622302B (zh)	2013-01-23	生产喷雾干燥产品的制剂工艺方法
Chang et al.	2014	Anti-hygroscopic effect of leucine on spray-dried herbal extract powders
JP2021522248A5 (2)	2022-04-28
MA38397A1 (fr)	2018-01-31	Agglomérats inhalables de particules de support poreuses et médicament micronisé
JP2018537565A (ja)	2018-12-20	表面反応炭酸カルシウムを含む細粒の製造方法
JPWO2019207061A5 (2)	2022-04-28
JP2004523594A5 (2)	2009-07-23
JP2018534348A5 (2)	2019-11-07
JP2009530271A5 (2)	2012-03-15
JP2005508977A (ja)	2005-04-07	医薬品化合物中の熱分解法シリカに基づく粒体材料の使用
RU2016142819A (ru)	2018-05-10	Твердая композиция, содержащая аморфный софосбувир
CN102861106A (zh)	2013-01-09	一种复方氨酚烷胺微丸的制备方法
RU2018144108A (ru)	2020-07-30	Никотиносодержащие частицы
JP2012509922A5 (2)	2013-01-17
JP2013523676A5 (2)	2014-04-24
HRP20161624T1 (hr)	2017-01-27	Produkt ko-mikronizacije koji sadrži ulipristal acetat
CN103948933A (zh)	2014-07-30	一种白藜芦醇包合物及其制剂的制备方法
CN104800184B (zh)	2018-03-30	琥珀酸呋罗曲坦缓释剂片
JP2024513468A (ja)	2024-03-25	ニコチン含有凝集体およびその形成方法
CN102772392B (zh)	2014-09-24	一种阿比多尔缓控释胶囊及其制备方法
CN103891786A (zh)	2014-07-02	一种驱蚊喷雾剂及其制备方法
CN103655495B (zh)	2015-06-10	一种辅料种类和用量少的硫辛酸片剂及其制备方法
CN102145017B (zh)	2012-08-29	改善中药提取液喷雾干燥过程中热熔型粘壁的方法
CN101954104A (zh)	2011-01-26	一种丹皮酚固体分散体空气清新剂